The company’s shares dropped by 5% in premarket trading. Shares have lost about 90% of their value this year as the escalating popularity of weight-loss treatments from Eli Lilly & Co. and Novo Nordisk A/S have decimated demand for its trademark diet plans.
WeightWatchers missed analysts’ subscriber estimates in the second quarter, as revenue fell 11% compared to the prior year. The company’s business has been in steady decline since 2019, as the Covid-19 pandemic dramatically reduced the number of subscribers to its in-person meetings. WeightWatchers’ once-growing online offering has plateaued, and the company is relying on its recently acquired telehealth business to improve its cash flow.
© 2024 Bloomberg L.P.